- Recommended only for certain high risk group of children, during outbreaks, and international travelers, including students going for study abroad and travelers to Hajj and sub-Sahara Africa.
- Both Meningococcal conjugate vaccines (Quadrivalent MenACWY-D, Menactra® by Sanofi Pasteur and monovalent group A, PsA–TT, MenAfriVac® by Serum Institute of India) and polysaccharide vaccines (bi- and quadrivalent) are licensed in India. PsA–TT is not freely available in market.
- Conjugate vaccines are preferred over polysaccharide vaccines due to their potential for herd protection and their increased immunogenicity, particularly in children <2 years of age.
- As of today, quadrivalent conjugate and polysaccharide vaccines are recommended only for children 2 years and above. Monovalent group A conjugate vaccine, PsA–TT can be used in children above 1 year of age.